Norethandrolone (Pronabol) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
NORETHANDROLONE, a nandrolone derivative, is a synthetic hormone with anabolic and androgenic properties and moderate progestational activity. It was used to treat, among others, anorexia nervosa, severe burns and trauma, decubitus ulcers, osteoporosis, gastrointestinal diseases. Its list of prescriptions included preparation for and recovery from surgery, bone fracture healing, severe or prolonged illness, and various forms of malnourishment in adults and children. It was withdrawn for the market in most countries in the 1960s, however, it remains viable on the veterinary drug market in Australia.   NCATS

Chemistry

  • SMILES: CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
  • InChIKey: ZDHCJEIGTNNEMY-XGXHKTLJSA-N
  • Mol. Mass: 302.451
  • ALogP: 4.27
  • ChEMBL Molecule:
    norethandrolone  
More Chemistry

Pharmacology

Alternative names

nilevar | norethandrolone | pronabol

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Anorexia Nervosa

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Geriatrics (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue